Recent Updates from CROWN Trial: Lorlatinib in Treatment-Naïve Patients with Advanced ALK+ NSCLC

Learn about the recent updates from the CROWN trial on lorlatinib in treatment-naïve patients with advanced ALK+ NSCLC. Expert perspectives from The Oncology Brothers and Joshua K. Sabari, MD, shed light on the efficacy of lorlatinib and its potential as a groundbreaking treatment option for this specific patient population. Discover the promising outcomes and favorable response rates observed, emphasizing the importance of early intervention with lorlatinib in managing advanced ALK+ NSCLC.